Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $82,100.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 5,000 shares of the stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $16.42, for a total value of $82,100.00. Following the transaction, the chief executive officer now directly owns 985,392 shares of the company’s stock, valued at approximately $16,180,136.64. The trade was a 0.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Samuel Kintz also recently made the following trade(s):

• On Monday, March 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.83, for a total value of $260,375.00.

Enliven Therapeutics Trading Down 1.9 %

Shares of NASDAQ ELVN traded down $0.31 during trading hours on Monday, hitting $16.22. 282,227 shares of the company traded hands, compared to its average volume of 264,497. The company’s 50 day moving average price is $19.77 and its 200 day moving average price is $22.98. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03. The stock has a market capitalization of $794.84 million, a price-to-earnings ratio of -8.54 and a beta of 1.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.07. The firm had revenue of $0.03 million during the quarter. Equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers grew its position in Enliven Therapeutics by 4.9% in the 1st quarter. Rhumbline Advisers now owns 52,502 shares of the company’s stock valued at $1,033,000 after acquiring an additional 2,466 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Enliven Therapeutics by 3,058.1% during the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock valued at $53,000 after buying an additional 2,630 shares in the last quarter. Wellington Management Group LLP boosted its position in Enliven Therapeutics by 15.3% in the 4th quarter. Wellington Management Group LLP now owns 80,916 shares of the company’s stock valued at $1,821,000 after buying an additional 10,746 shares during the period. California State Teachers Retirement System grew its stake in Enliven Therapeutics by 10.2% in the 4th quarter. California State Teachers Retirement System now owns 20,914 shares of the company’s stock worth $471,000 after acquiring an additional 1,940 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Enliven Therapeutics by 67.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company’s stock worth $984,000 after acquiring an additional 17,546 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright upped their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, March 21st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.